Management Team

Through Our Focus and Dedications to Cures.

Zonghai Li, M.D. & Ph.D.

President & CEO
Entrepreneur of a series of life tech start-up companies;
Professor, Shanghai Cancer Institute, Renji Hospital affiliated to SJTU;
Approximate 20 years in cancer biology and therapeutics;
Council member of Gene Therapy Association of China;
Council member of China Translational Medicine Union;
Council member of Shanghai Immunology Association;
M.D. degree from Fudan University.

Huamao Wang, Ph.D.

COO
Over 10 years in gene therapy and protein science research;
5 years’ experience in life-tech operations;
Broad Biotech drug discovery experience including vaccine, antibody, bispecific antibody, ADC and CAR-T cell therapy;
Broad R&D experience in assay and diagnostic product developments;
Previous Assistant Professor of Zhejiang Academy of Medical Science;
Ph.D. degree from Fudan University.

Haiou Chen

V.P. Finance
More than 15 years’ experience in capital operation and financial management ;
Founding Partner of Pengfei Certified Public Accountants;
Previously served as CFO of Pavay Gene Pharmaceutical;
M.B.A from Central South University.

Qinhua Cindy Ru, Ph.D

EVP & CSO
20 years of intensive experience in Global Oncology Clinical Development, Registration Submission and Product Launch;
Merck & Co., Inc. (Upper Gwynedd PA, USA) clinical research scientist in Oncology Clinical Department, major clinical contributor for MAA submission preparation of vorinostat in Merck Oncology;
Novartis Oncology Business Unit (Florham Park NJ, USA) Global Clinical Trial Head of burparlisib (BKM120), completed the first-in-man trial significantly ahead of timeline, winner of Novartis President Award, managing multiple global phase II PoC trials and Phase III pivotal trial of burparlisib (BKM120) in Breast Cancer, Glioblastoma, and NSCLC for consecutive 6 years;
Exelixis (South San Francisco CA, USA) Senior Director, Clinical Science Lead of Phase III pivotal trial METEOR, which was granted BTD, Priority Review and Rolling Submission by the US FDA, and the Accelerate Assessment by the EU EMA;
Pfizer Oncology Late Phase Clinical Development (La Jolla CA, USA) Senior Director, Hematology Asset Team Lead, “CEO” of inotuzumab ozogamicin Global Asset Team, timely delivered two top line reports for Phase III pivotal INO-VATE trial, which was granted BTD, Priority Review and Rolling Submission by the US FDA, and timely submitted inotozumab ozogamicin MAA to the EU EMA;
Sihuan Pharmaceutical Holding Group Ltd. (Beijing, China) Chief Scientific Officer, General Manager of Clinical Center;
Principle scientist and sub-investigator of Clinical Breast Care Project (CBCP), a breast cancer vaccination clinical development program sponsored by the US Department of Defense and cofounded by Walter Reed Army Medical Center (Washington DC) and Windber Medical Center (Windber PA), prior to joining in the global pharmaceutical industry;
Ph.D degree in Chemistry from Tsinghua University;Post-Doctoral training in the US Department of Defense sponsored Los Alamos National Laboratory Bioscience Division.

Jie JIA, Ph.D

VP-Business Development
Over 10 years R&D management experience with more than 25 research publication, including Cell, Nature, etc;
Expertise in market analysis, pipeline assessment, technology evaluation, CRO/CMO management, budgetary control and research compliance;
Previous Project Staff at Cleveland Clinic Foundation, Editorial Board Members for a couple of research journals;
Ph.D from Chinese Academy of Sciences, Postdoctoral Fellowship at Cleveland Clinic.